| 1 |
Clinical Phase II Development of NT‑101: An Innovative Topical Therapy for wet Age‑Related Macular Degeneration |
| rProtein |
wet AMD |
PEDF pathway (angiogenesis and neuroprotection) |
Phase 2 |
NexThera Co., Ltd. |
RS-2026-25502180 |
|
| 2 |
Preclinical study supporting IND clearance for phase 2 clinical trial of HBPB1-007 peptide eye-drop therapy in geographic atrophy secondary to age-related macular degeneration |
| rProtein |
Geographic Atrophy secondary to dry Age-related Macular Degeneration |
TIR domain of Toll-like receptor (TLR) and its adaptor proteins |
Preclinical |
Huons BioPharma |
RS-2026-25502083 |
|
| 3 |
Development of multi-specific fusion protein modulating multiple angiogenesis pathways for the treatment of retinal vascular diseases |
| rProtein |
wAMD, DME, DR |
VEGF-A, VEGF-B, PlGF, Ang-2 |
Candidate |
ALTEOGEN BIOLOGICS |
RS-2025-25449916 |
|
| 4 |
Development of inflammatory cell-targeting exosome-based therapeutics for Ophthalmology via **** inhibition |
| rProtein |
Confidential |
N/A |
Lead |
ILIAS Biologics |
RS-2024-00337789 |
|
| 5 |
Recombinant human HAPLN1 protein: a multi-functional therapeutic candidate to treat dry eye disease |
| rProtein |
Dry eye disease |
HAPLN1 |
Candidate |
HaplnScience Inc. |
RS-2023-00217306 |
|